Business Context and Reporting Period
This Form 8-K filing by Alnylam Pharmaceuticals, Inc. reports a material definitive agreement entered into on October 18, 2012, with Genzyme Corporation. The report was filed on October 22, 2012.
Key Financial Metrics and Agreement Terms
- Upfront Payment: Genzyme is required to pay an upfront cash payment of $22.5 million.
- Milestone Payments: Genzyme must make payments upon achieving specified development and regulatory milestones totaling up to $50.0 million.
- Royalties: Genzyme will pay tiered royalties with an effective rate ranging from the mid-teens to mid-twenties based on annual net sales of Licensed Products in the Genzyme Territory.
- Scope: The agreement covers exclusive rights in Japan and the Asia-Pacific region for RNAi therapeutics targeting transthyretin (TTR), specifically ALN-TTR02 and ALN-TTRsc.
Material Changes and Strategic Shifts
The primary material change is the establishment of a strategic partnership granting Genzyme exclusive development and commercialization rights for Alnylam's TTR program in the Asia-Pacific region. Alnylam retains all rights worldwide outside this territory. Genzyme assumes primary responsibility and expense for development activities within its territory, while a joint steering committee will govern the collaboration.
Outlook, Risks, and Contingencies
- Patent Expiry: Fundamental RNAi patents covering the compounds are estimated to expire between 2016 and 2021, with other patents expiring in 2032. Terms may be extended via patent term extensions or supplemental protection certificates.
- Termination Rights: Genzyme may terminate the agreement without cause with six months' prior written notice. Additionally, Genzyme may terminate with 45 days' notice if specified success criteria are not met following a Phase II clinical study.
- Exclusivity: During the term, neither party may develop or commercialize competing products for ATTR in the Genzyme Territory without prior written agreement.
- Supply and Manufacturing: The parties intend to enter a supply agreement. Genzyme has the option to manufacture the products itself or via a third party.
Investor Verification Checklist
- Verify the receipt of the $22.5 million upfront payment and its impact on cash flow.
- Confirm the specific development milestones required to trigger the $50.0 million in potential payments.
- Review the detailed definition of "success criteria" for the Phase II study that allows Genzyme to terminate the agreement.
- Assess the timeline for the intended supply agreement and manufacturing arrangements.
- Monitor the status of patent filings and potential extensions to validate the 2016-2021 and 2032 expiry estimates.